Rapid Establishment of CHO Cell Lines Producing the Anti-Hepatocyte Growth Factor Antibody SFN68 |
Song, Seong-Won
(Graduate Program in Biomaterials Science and Engineering, Yonsei University)
Lee, Song-Jae (Bioresearch Institute, Yooyoung Pharmaceuticals Co. Ltd.) Kim, Chang-Young (Bioresearch Institute, Yooyoung Pharmaceuticals Co. Ltd.) Han, Byungryeul (iBio Inc, Samsung Cancer Research Building) Oh, Jong-Won (Graduate Program in Biomaterials Science and Engineering, Yonsei University) |
1 | Cacciatore JJ, Chasin LA, Leonard EF. 2010. Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system. Biotechnol. Adv. 28: 673-681. DOI ScienceOn |
2 | Backliwal G, Hildinger M, Chenuet S, Wulhfard S, De Jesus M, Wurm FM. 2008. Rational vector design and multipathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res. 36: e96. DOI ScienceOn |
3 | Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. 1991. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251: 802-804. DOI |
4 | Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, et al. 2006. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 66: 1721-1729. DOI ScienceOn |
5 | Gerber MA, Arunakumari A, Huang D, Goldstein J, McNorton S, Drew B, et al. 2008. Integrated strategies for clone and media formulation selection. Bioprocess Int. 6: 58-63. |
6 | Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, et al. 2001. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA 98: 7443-7448. DOI ScienceOn |
7 | Cherrington JM, Strawn LM, Shawver LK. 2000. New paradigms for the treatment of cancer: the role of antiangiogenesis agents. Adv. Cancer Res. 79: 1-38. DOI |
8 | Comoglio PM, Giordano S, Trusolino L. 2008. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7: 504-516. DOI ScienceOn |
9 | Huang YM, Hu W, Rustandi E, Chang K, Yusuf-Makagiansar H, Ryll T. 2010. Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol. Prog. 26: 1400-1410. DOI ScienceOn |
10 | Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. 2005. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol. Hematol. 53: 35-69. DOI ScienceOn |
11 | Kim K, Hur Y, Ryu EK, Rhim JH, Choi CY, Baek CM, et al. 2007. A neutralizable epitope is induced on HGF upon its interaction with its receptor cMet. Biochem. Biophys. Res. Commun. 354: 115-121. DOI ScienceOn |
12 | Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, et al. 2006. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res. 12: 1292-1298. DOI ScienceOn |
13 | Omasa T. 2002. Gene amplification and its application in cell and tissue engineering. J. Biosci. Bioeng. 94: 600-605. DOI |
14 | Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. 2000. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 60: 6737-6743. |
15 | Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. 2006. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 12: 6144-6152. DOI ScienceOn |
16 | Morrow JK. 2008. Optimizing transient gene expression: applications expected to move beyond discovery and the preclinical to clinical realm. Genet. Eng. Biotechnol. News. 28: 54-59. |
17 | Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, et al. 2009. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69: 8009-8016. DOI ScienceOn |
18 | Rubin JS, Bottaro DP, Aaronson SA. 1993. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim. Biophys. Acta. 1155: 357-371. |
19 | Renard JM, Spagnoli R, Mazier C, Salles MF, Mandine E. 1988. Evidence that monoclonal antibody production kinetics is related to the integral of the viable cells in batch systems. Biotechnol. Lett. 10: 91-96. DOI ScienceOn |
20 | Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, et al. 1992. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol. Cell. Biol. 12: 5152-5158. DOI |
21 | Munshi N, Jeay S, L i Y, Chen CR, France DS, Ashwell MA, et al. 2010. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 9: 1544-1553. DOI |
22 | Sauer PW, Burky JE, Wesson MC, Sternard HD, Qu L. 2000. A high-yielding, generic fed-batch cell culture process for production of recombinant antibodies. Biotechnol. Bioeng. 67: 585-597. DOI ScienceOn |
23 | Tian H, Cronstein BN. 2007. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 65: 168-173. |
24 | Tsarfaty I, Rong S, Resau JH, Rulong S, da Silva PP, Vande Woude GF. 1994. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science 263: 98-101. DOI |